Literature DB >> 8525397

Plasma concentrations of praziquantel during the therapy of neurocysticerosis with praziquantel, in the presence of antiepileptics and dexamethasone.

K Na-Bangchang1, S Vanijanonta, J Karbwang.   

Abstract

Plasma praziquantel concentrations were measured in 11 Thai patients with active neurocysticercosis (8 males and 3 females). Praziquantel (Biltricide 600 mg per tablet) was given at a daily dose of 45 mg/kg given in 3 divided doses for 15 consecutive days. All patients had significant improvement with resolution of symptoms and signs, and reduction of active lesions of cysticercosis shown by the brain computed tomographic scanning. After oral administration, the drug was rapidly absorbed from the gastrointestinal tract. There was substantial inter-individual variability in plasma concentrations of praziquantel. After the first dose, maximum plasma concentrations in the range of 42-540 ng/ml was attained at 30 minutes to 5 hours. In all cases, the drug almost totally disappeared from plasma within 8 hours; drug levels measured prior to the first doses on the following days showed undetectable levels. The area under the plasma concentration-time curves of praziquantel following the first dose were between 125 and 990 ng hour/ml. The results suggested that the unusual low plasma availability of the drug observed in this group of patients could be a consequence of pharmacokinetic drug interactions of the concomitant therapy with antiepileptic drugs and dexamethasone. Active metabolite(s), rather than praziquantel itself, may play a significant part in the therapy of neurocysticerosis.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8525397

Source DB:  PubMed          Journal:  Southeast Asian J Trop Med Public Health        ISSN: 0125-1562            Impact factor:   0.267


  5 in total

1.  Sensitive in vitro system to assess morphological and biochemical effects of praziquantel and albendazole on Taenia solium cysts.

Authors:  S Mahanty; A Paredes; M Marzal; E Gonzalez; S Rodriguez; P Dorny; C Guerra-Giraldez; H H Garcia; T Nash
Journal:  Antimicrob Agents Chemother       Date:  2010-11-01       Impact factor: 5.191

2.  Identification of human cytochrome P(450)s that metabolise anti-parasitic drugs and predictions of in vivo drug hepatic clearance from in vitro data.

Authors:  Xue-Qing Li; Anders Björkman; Tommy B Andersson; Lars L Gustafsson; Collen M Masimirembwa
Journal:  Eur J Clin Pharmacol       Date:  2003-08-12       Impact factor: 2.953

3.  Neurocysticercosis and afebrile seizure.

Authors:  Viroj Wiwanitkit
Journal:  Rev Inst Med Trop Sao Paulo       Date:  2015 Jan-Feb       Impact factor: 1.846

Review 4.  Lack of Clinical Pharmacokinetic Studies to Optimize the Treatment of Neglected Tropical Diseases: A Systematic Review.

Authors:  Luka Verrest; Thomas P C Dorlo
Journal:  Clin Pharmacokinet       Date:  2017-06       Impact factor: 6.447

5.  Activity of praziquantel enantiomers and main metabolites against Schistosoma mansoni.

Authors:  Isabel Meister; Katrin Ingram-Sieber; Noemi Cowan; Matthew Todd; Murray N Robertson; Claudia Meli; Malay Patra; Gilles Gasser; Jennifer Keiser
Journal:  Antimicrob Agents Chemother       Date:  2014-06-30       Impact factor: 5.191

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.